BACKGROUND: The need for an HSV-2 vaccine is great considering the increasing prevalence of HSV-2 despite the widespread use of antiviral drugs. Human clinical trials of HSV-2 vaccines that elicit neutralizing antibodies have proven to be only partially effective suggesting that induction of effective T cell responses to HSV-2 is also a critical component to an efficacious vaccine. A sensitive and specific assay to measure HSV-specific T cell responses is a necessary part of vaccine development and thus we undertook the development of an interferon-γ (IFN-γ) ELISPOT assay to measure T cell responses to HSV-2. METHODS: PBMC from HSV-seronegative (HSVneg) (n=35), HSV-1-seropositive (HSV-1+/2-) (n=20) and HSV-2-seropositive (HSV-2+) subjects (n=26) were screened by IFN-γ ELISPOT for T cell responses using 34 peptide pools representing 16 HSV-2 proteins including mostly virion and immediate-early (IE) proteins. RESULTS: Overall, 85% of HSV-2+ subjects had a positive response to the HSV-2 peptide pools and on average, HSV-2+ subjects responded to 3 peptide pools (range 1-10). The most frequent responses were to gD-2, UL39, UL46, ICP0, UL49, gB-2, and ICP4. In contrast, only 2 of 35 (6%) HSVneg subjects had detectable T cell responses and in both cases, responses were of low magnitude relative to responses in HSV-2+ subjects and were directed at a single peptide pool. The response rate to the HSV-2 peptide pools in HSV-1+/2- subjects was 40% suggesting that the HSV-2 peptide pools contain a significant number of type-common T cell epitopes. The IFN-γ ELISPOT assay detected CD4 and CD8 T cells directed at HSV-2 peptides as confirmed by intracellular cytokine staining and flow cytometry. CONCLUSION: We have developed a quantitative IFN-γ ELISPOT assay that detects both CD4 and CD8 T cells to HSV-2 peptides. This assay does not require large quantities of PBMC to generate dendritic cells for T cell stimulation, making it an ideal assay for monitoring the immunogenicity of candidate HSV-2 vaccines designed to elicit T cell responses to HSV-2 specific epitopes.
BACKGROUND: The need for an HSV-2 vaccine is great considering the increasing prevalence of HSV-2 despite the widespread use of antiviral drugs. Human clinical trials of HSV-2 vaccines that elicit neutralizing antibodies have proven to be only partially effective suggesting that induction of effective T cell responses to HSV-2 is also a critical component to an efficacious vaccine. A sensitive and specific assay to measure HSV-specific T cell responses is a necessary part of vaccine development and thus we undertook the development of an interferon-γ (IFN-γ) ELISPOT assay to measure T cell responses to HSV-2. METHODS: PBMC from HSV-seronegative (HSVneg) (n=35), HSV-1-seropositive (HSV-1+/2-) (n=20) and HSV-2-seropositive (HSV-2+) subjects (n=26) were screened by IFN-γ ELISPOT for T cell responses using 34 peptide pools representing 16 HSV-2 proteins including mostly virion and immediate-early (IE) proteins. RESULTS: Overall, 85% of HSV-2+ subjects had a positive response to the HSV-2 peptide pools and on average, HSV-2+ subjects responded to 3 peptide pools (range 1-10). The most frequent responses were to gD-2, UL39, UL46, ICP0, UL49, gB-2, and ICP4. In contrast, only 2 of 35 (6%) HSVneg subjects had detectable T cell responses and in both cases, responses were of low magnitude relative to responses in HSV-2+ subjects and were directed at a single peptide pool. The response rate to the HSV-2 peptide pools in HSV-1+/2- subjects was 40% suggesting that the HSV-2 peptide pools contain a significant number of type-common T cell epitopes. The IFN-γ ELISPOT assay detected CD4 and CD8 T cells directed at HSV-2peptides as confirmed by intracellular cytokine staining and flow cytometry. CONCLUSION: We have developed a quantitative IFN-γ ELISPOT assay that detects both CD4 and CD8 T cells to HSV-2peptides. This assay does not require large quantities of PBMC to generate dendritic cells for T cell stimulation, making it an ideal assay for monitoring the immunogenicity of candidate HSV-2 vaccines designed to elicit T cell responses to HSV-2 specific epitopes.
Authors: Helen Horton; Evan P Thomas; Jason A Stucky; Ian Frank; Zoe Moodie; Yunda Huang; Ya-Lin Chiu; M Juliana McElrath; Stephen C De Rosa Journal: J Immunol Methods Date: 2007-04-03 Impact factor: 2.303
Authors: Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz Journal: JAMA Date: 2006-08-23 Impact factor: 56.272
Authors: David M Koelle; Amalia Magaret; Christopher L McClurkan; Michael L Remington; Terri Warren; Florentina Teofilovici; Anna Wald Journal: Clin Vaccine Immunol Date: 2008-03-19
Authors: Ashok Cattamanchi; Christine M Posavad; Anna Wald; Yaela Baine; Jennifer Moses; Terry J Higgins; Richard Ginsberg; Richard Ciccarelli; Lawrence Corey; David M Koelle Journal: Clin Vaccine Immunol Date: 2008-09-10
Authors: Ajit P Limaye; Katharine A Kirby; Gordon D Rubenfeld; Wendy M Leisenring; Eileen M Bulger; Margaret J Neff; Nicole S Gibran; Meei-Li Huang; Tracy K Santo Hayes; Lawrence Corey; Michael Boeckh Journal: JAMA Date: 2008-07-23 Impact factor: 56.272
Authors: Hari Ramachandran; Jessica Laux; Ioana Moldovan; Richard Caspell; Paul V Lehmann; Ramu A Subbramanian Journal: Cells Date: 2012-07-25 Impact factor: 6.600
Authors: Janna Heide; Nils H Wildner; Christin Ackermann; Melanie Wittner; Matthias Marget; Alessandro Sette; John Sidney; Thomas Jacobs; Julian Schulze Zur Wiesch Journal: Front Immunol Date: 2020-01-22 Impact factor: 7.561
Authors: Janna Heide; Sophia Schulte; Matin Kohsar; Thomas Theo Brehm; Marissa Herrmann; Hendrik Karsten; Matthias Marget; Sven Peine; Alexandra M Johansson; Alessandro Sette; Marc Lütgehetmann; William W Kwok; John Sidney; Julian Schulze Zur Wiesch Journal: PLoS Pathog Date: 2021-09-16 Impact factor: 6.823